Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEP-363856 extension study in schizophrenia
NCT02970929Phase 2Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jan 2017
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of ulotaront in schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Incidence of Overall Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs) Leading to Discontinuation at 27 weeks. Started Jan 2017; status: completed.
02
Drugs
ulotaront
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02970929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02970929.